<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792932</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-2</org_study_id>
    <nct_id>NCT03792932</nct_id>
  </id_info>
  <brief_title>Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer</brief_title>
  <official_title>A Multicenter Prospective RCT Study of Laparoscopic Versus Open Distal Pancreatectomy in Patients With Pancreatic Cancer at the Body and Tail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open distal pancreatectomy (ODP) has been commonly employed for the treatment of a variety of
      cancers in body and tail of pancreas. Although many general surgical procedures have been
      increasingly performed laparoscopically or with laparoscopic assistance, until the current
      decade, laparoscopic pancreatic surgery had not been performed for its complicated anatomy.
      But laparoscopic distal pancreatectomy (LDP) has been widely accepted as a standard treatment
      for body and tail pancreatic cancer because there is no anastomosis in it, and LDP has
      gradually become the first choice for these cancers in clinical work. Although there are
      several studies about the comparison between LDP and ODP, most are retrospective and there is
      no agreement in surgical margin, lymph node numbers and prognosis to identify the oncological
      differences between the two surgical approaches. The investigators' pilot study showed that
      patients with body and tail pancreatic cancer underwent LDP had a better prognosis compared
      with the ones undergoing ODP, with no statistics differences in postoperative complications
      and mortality. This perspective RCT study is performed to confirm whether LDP would improve
      the prognosis for patients with body and tail pancreatic cancer compared with ODP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>RFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>2 years</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detected lymph node number</measure>
    <time_frame>2 years</time_frame>
    <description>Detected lymph node number</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Surgery</condition>
  <condition>Laparoscopy</condition>
  <arm_group>
    <arm_group_label>Laparoscopic distal pancreatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open distal pancreatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic distal pancreatectomy</intervention_name>
    <description>Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).</description>
    <arm_group_label>Laparoscopic distal pancreatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open distal pancreatectomy</intervention_name>
    <description>Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).</description>
    <arm_group_label>Open distal pancreatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 19 years and ≤ 80 years, no gender limitation

          2. Resectable body and tail pancreatic cancer (refer to NCCN 2018)

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          4. Tumor locates at the body and tail of the pancreas without distant metastasis

          5. No celiac trunk and superior mesenteric artery invasion

          6. No operation contraindication, fit for laparoscopic surgery

          7. The expected survival after surgery ≥ 3 months

          8. Patients who are willing and able to comply with the study procedure

          9. Signed informed content obtained prior to treatment

        Exclusion Criteria:

          1. Locally advanced unresectable body and tail pancreatic cancer

          2. Multi-organ and vascular resection needed

          3. Patients undergoing total pancreatectomy

          4. Benign tumor at the body and tail of the pancreas or pancreatic cancer at the head of
             the pancreas

          5. Distant metastasis or ascites detected by imaging

          6. Severe important organ function impairment (heart, liver, kidney)

          7. Patients who are with other primary malignancy or haematological disorders

          8. Pregnant or nursing women

          9. Patients who have received chemotherapy, radiotherapy and interventional therapy
             before the pancreatectomy

         10. Patients who have participated in other clinical trials for pancreatic cancer
             treatment within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
    <phone>+86-21-64175590</phone>
    <phone_ext>1307</phone_ext>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>He Cheng, M.D., Ph.D.</last_name>
    <phone>+86-21-64175590</phone>
    <phone_ext>1307</phone_ext>
    <email>chenghe@fudanpci.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Huo, Dr.</last_name>
      <phone>17621407517</phone>
      <email>generalsurgeon@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Shanghai Pancreatic Cancer Institute; Pancreatic Cancer Institute, Fudan University. Shanghai, China</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <phone_ext>1307</phone_ext>
      <email>yuxianjun@fudanpci.org</email>
    </contact>
    <contact_backup>
      <last_name>He Cheng, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <phone_ext>1307</phone_ext>
      <email>chenghe@fudanpci.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Tang, Dr.</last_name>
      <phone>13918874380</phone>
      <email>tlehbh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunqiang Cai, Dr.</last_name>
      <phone>17721950223</phone>
      <email>494374409@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui Municipal Central Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuan Jiang, Dr.</last_name>
      <phone>13905882233</phone>
      <email>jiangch223@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ricci C, Casadei R, Taffurelli G, Toscano F, Pacilio CA, Bogoni S, D'Ambra M, Pagano N, Di Marco MC, Minni F. Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: a systematic review and meta-analysis. J Gastrointest Surg. 2015 Apr;19(4):770-81. doi: 10.1007/s11605-014-2721-z. Epub 2015 Jan 6. Review.</citation>
    <PMID>25560180</PMID>
  </reference>
  <reference>
    <citation>van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, Alseidi A, Ateeb Z, Balzano G, Berrevoet F, Björnsson B, Boggi U, Busch OR, Butturini G, Casadei R, Del Chiaro M, Chikhladze S, Cipriani F, van Dam R, Damoli I, van Dieren S, Dokmak S, Edwin B, van Eijck C, Fabre JM, Falconi M, Farges O, Fernández-Cruz L, Forgione A, Frigerio I, Fuks D, Gavazzi F, Gayet B, Giardino A, Groot Koerkamp B, Hackert T, Hassenpflug M, Kabir I, Keck T, Khatkov I, Kusar M, Lombardo C, Marchegiani G, Marshall R, Menon KV, Montorsi M, Orville M, de Pastena M, Pietrabissa A, Poves I, Primrose J, Pugliese R, Ricci C, Roberts K, Røsok B, Sahakyan MA, Sánchez-Cabús S, Sandström P, Scovel L, Solaini L, Soonawalla Z, Souche FR, Sutcliffe RP, Tiberio GA, Tomazic A, Troisi R, Wellner U, White S, Wittel UA, Zerbi A, Bassi C, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study. Ann Surg. 2019 Jan;269(1):10-17. doi: 10.1097/SLA.0000000000002561.</citation>
    <PMID>29099399</PMID>
  </reference>
  <reference>
    <citation>Sulpice L, Farges O, Goutte N, Bendersky N, Dokmak S, Sauvanet A, Delpero JR; ACHBT French Pancreatectomy Study Group. Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: Time for a Randomized Controlled Trial? Results of an All-inclusive National Observational Study. Ann Surg. 2015 Nov;262(5):868-73; discussion 873-4. doi: 10.1097/SLA.0000000000001479.</citation>
    <PMID>26583678</PMID>
  </reference>
  <reference>
    <citation>Shin SH, Kim SC, Song KB, Hwang DW, Lee JH, Lee D, Lee JW, Jun E, Park KM, Lee YJ. A comparative study of laparoscopic vs. open distal pancreatectomy for left-sided ductal adenocarcinoma: a propensity score-matched analysis. J Am Coll Surg. 2015 Feb;220(2):177-85. doi: 10.1016/j.jamcollsurg.2014.10.014. Epub 2014 Oct 31.</citation>
    <PMID>25529901</PMID>
  </reference>
  <reference>
    <citation>Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg. 2012 Jun;255(6):1048-59. doi: 10.1097/SLA.0b013e318251ee09. Review.</citation>
    <PMID>22511003</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 27, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>Chair of Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

